- Home
- NXTC
NXTC
NextCure Inc.
as 11-15-2024 4:00pm EST
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | BELTSVILLE |
| Market Cap: | 40.3M | IPO Year: | 2019 |
| Target Price: | $4.00 | AVG Volume (30 days): | 44.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.09 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.03 - $2.57 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest NextCure Inc. News
NXTC Breaking Stock News: Dive into NXTC Ticker-Specific Updates for Smart Investing
GlobeNewswire
10 days ago
NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results
GlobeNewswire
12 days ago
NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting
GlobeNewswire
a month ago
NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting
GlobeNewswire
2 months ago
NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024
Simply Wall St.
2 months ago
Is NextCure (NASDAQ:NXTC) In A Good Position To Deliver On Growth Plans?
GlobeNewswire
4 months ago
NextCure Provides Business Update and Reports Second Quarter 2024 Financial Results
GlobeNewswire
5 months ago
NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
GlobeNewswire
6 months ago
NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024
Compare NXTC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NXTC NextCure Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.